Details of the Drug Combination

General Information of Drug Combination (ID: DCO7ED3)

• Drug Combination Name: Terameprocol + Hepzato
• Indication: Adenocarcinoma; Status: Investigative [1]
• Component Drugs:
  Terameprocol (DMC3P45): Small molecular drug
  Hepzato (DM2AZPP): N.A.
• High-throughput Screening Result:
  Testing Cell Line: A549
  Zero Interaction Potency (ZIP) Score: 4.92
  Bliss Independence Score: 6.96
  Loewe Additivity Score: 0.43
  LHighest Single Agent (HSA) Score: 0.17

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[2]

Indication(s) of Hepzato

Disease Entry	ICD 11	Status	REF
Uveal Melanoma	2D0Y	Phase 3	[3]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Carcinoma	DCZJH4X	MCF7	Investigative	[4]
Colon carcinoma	DCX18VR	KM12	Investigative	[4]
Adenocarcinoma	DCA5K55	DU-145	Investigative	[1]
Lung adenocarcinoma	DCY48LA	NCI-H522	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
• [3] ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
• [4] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.